Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000950170-25-093844)

Filing Details

Accession Number:: 0000950170-25-093844
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-07-03 16:07:21
Reporting Period:: 2025-07-02

Filing Date:: 2025-07-03
Accepted Time:: 2025-07-03 16:07:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	In Vitro & In Vivo Diagnostic Substances (2835)	364785571

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2019493	P Michael Dube	C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139	Vp, Chief Accounting Officer	No	No	No	No

Transaction Summary

Sold:	2,503 shares	Avg. Price: $9.95	Total Value: $24,904.85
Number of Shares After Transactions:	57,137 shares

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-07-02	2,503	$9.95	57,137	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2025, and does not represent a volitional trade by the Reporting Person.